AM Squared’s Legend Biotech LEGN Stock Holding History

AM Squared’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,600	Closed	-$70.9K	–	85
2024 Q2	$70.9K	Buy	+1,600	New	+$73.8K	0.18%	45

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AM Squared's LEGN Position: Q3 2024 in Review

AM Squared sold out of Legend Biotech (LEGN) in Q3 2024, closing a stake of 1,600 shares — an estimated $70.9K sold.

AM Squared first reported a position in LEGN in Q2 2024 and held it in 1 quarter. The position peaked at $70.9K in Q2 2024. 208 funds tracked by Wall St. Rank hold LEGN as of Q3 2024.

AM Squared reported no remaining Legend Biotech position as of Q3 2024 after selling out during the quarter.
AM Squared sold 1,600 Legend Biotech shares in Q3 2024, an estimated $70.9K.
AM Squared first reported a position in Legend Biotech in Q2 2024 and held it in 1 quarter.
AM Squared's Legend Biotech position peaked at $70.9K in Q2 2024.
208 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2024.

Based on AM Squared's 13F filing for Q3 2024, filed 7 Nov 2024.